Treatment of early-stage HER2+ breast cancer-an evolving field.

Ecancermedicalscience · 2015 · PMC4406526 · PMID 25932047

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

After a median follow-up of six years and when comparing arm B (n = 954) to C (n = 949), those receiving concurrent trastuzumab (arm C) presented a strong trend towards a reduction in the risk of DFS (HR 0.77, 99.9% CI 0.53–1.11; p-value 0.0216; the p-value superior to the prespecified boundary of 0.00116 for interim analysis).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.